pharmaphorum

OCTOBER 19, 2022

Emma Hyland, VP strategy, commercial content at Veeva Systems, tells us modular content is the most significant wave of innovation hitting the content world in life sciences, and rightly so because HCPs’ needs and expectations have changed. “There isn’t a one-size-fits-all for how the life sciences industry creates content.

Life Science 97

Life Science Compliance Production Pharma Companies 97

pharmaphorum

FEBRUARY 25, 2022

The past two years have shone a spotlight on the UK life sciences industry. Pharma companies are now household names, having been thrust into the public’s consciousness after dominating the headlines through the pandemic. An industry that will forever play a greater role in our everyday lives. About the author.

Life Science 98

Life Science Vaccination Vaccine Pharmacy 98

pharmaphorum

NOVEMBER 30, 2022

Veeva Systems invited pharmaphorum to attend its industry summit in Madrid this week, a huge event that gathered together over 1,000 individuals from life sciences and pharma. The question is, how can the journey there be accelerated, when on the horizon awaits a life sciences future very much immersed in speciality medicine?

Life Science 98

Life Science Pharma Companies Sales Marketing 98

Pharmaceutical Technology

JANUARY 31, 2023

The US omnibus bill passed in late December 2022 will give the agency greater powers to regulate accelerated approval drugs, while the Inflation Reduction Act’s lowering of drug prices will create an uncertain environment for drug developers, he said. That leaves three years for pharma companies to prepare. It’s much needed.

Drugs 130

Drugs Regulation Gene Therapy Insulin 130

pharmaphorum

DECEMBER 9, 2022

The PharmaStars accelerator was set up last year to help bridge the gap between digital health start-ups and potential pharma partners, which can be instrumental in making sure their technologies meet their potential – and help them to navigate the challenges of developing them in the highly regulated healthcare environment.

Life Science 52

Life Science DNA Genome Genomics 52

pharmaphorum

AUGUST 31, 2021

For the innovators and early adopters of the life sciences industry, engineering a regulatory-grade ECA can be daunting. However, if history is any indication, pharma companies have been risk-averse when it comes to fully immersing itself into the expanded use of RWE in our development efforts.

Clinical Trials 89

Clinical Trials Clinical Trials Life Science Trials 89

pharmaphorum

JULY 8, 2022

We have also seen the regulators actively support the use of these hybrid decentralised research approaches. Importantly, they enable pharma to be more patient-centric and design trials that are more conducive to people’s lifestyles, giving participants choice on how they want to participate in a study. Novel digital endpoints.

Clinical Trials 99

Clinical Trials Clinical Trials Trials Regulation 99

pharmaphorum

SEPTEMBER 15, 2020

Pharma’s go-to-market strategies have tended to be more traditional than those seen in non-regulated sectors, but there are some signs this is changing, with an acceleration in the pace of change forced by the COVID-19 pandemic that is allowing the industry to close its gap with faster, more nimble consumer brands. “The

Branding 129

Branding Marketing Pharma Companies Life Science 129

XTalks

OCTOBER 8, 2020

Aizon hopes that the rebrand will help drive its superior AI and ML-driven analytical platforms to help serve a wide range of industries within the life sciences and food sector. Some renames can lend organizations a new identity, particularly if a company is aiming to reinvent itself. The company’s chairman and CEO, Joseph C.

Manufacturing 98

Manufacturing Life Science Cosmetics Regulation 98

pharmaphorum

FEBRUARY 11, 2021

Pharma companies face many challenges when involving patients in the design of clinical trials – but doing so can have huge benefits further down the line, improving the sustainability and quality of research. There’s also that risk of a perceived coercion or influence. There’s sometimes a bit of a barrier,” he added.

Clinical Trials 101

Clinical Trials Clinical Trials Trials Clinical Research 101

XTalks

MAY 6, 2022

They discussed current challenges and solutions that life science companies and clinical development organizations have with the management of clinical data. To produce ethical results in a timely manner, life science companies should ensure that they have a robust and reliable clinical data pipeline in place.

Clinical Trials 98

Clinical Trials Clinical Trials Trials Life Science 98

pharmaphorum

NOVEMBER 23, 2022

A director in life sciences consulting for EY, she works within the commercial space for such companies, as well as their clients. “My However, it was around six or seven years ago that she began working specifically in pharma. There is still a struggle in pharma, an increasing demand for promotional materials.

Life Science 98

Life Science Marketing Medicine Production 98

pharmaphorum

APRIL 7, 2021

With other drugs in the pipeline too, van de Winkel said the company aims to continue to break new ground with next-generation antibody-based therapies. He notes that it already has 21 partnerships with pharma companies and will aim to keep more product rights than it did in the past. In good shape. We are in a crisis.

Antibody 90

Antibody Life Science Development Regulation 90

XTalks

SEPTEMBER 28, 2023

While digital media, such as short video formats on social media platforms, is being adopted by many segments and industries, pharma advertising remains more traditional, with print and TV advertising continuing to be favored by pharma companies.

Drugs 105

Drugs Allergies Branding FDA Approval 105

XTalks

MARCH 28, 2024

Bettica said the company’s focus is to now “make Duvyzat available as a treatment for DMD management in the US as quickly as possible.” In November, the FDA extended its decision deadline by three months to allow extra time for regulators to review additional information submitted by Italfarmaco as part of a new drug application.

FDA Approval 105

FDA Approval Genetics Gene Therapy Gene 105

pharmaphorum

DECEMBER 15, 2022

Co-chaired by Lord James O’Shaughnessy and Professor Mike Bewick, former deputy national medical director of NHS England (present online), the NHS Innovation and Life Sciences Commission Report launch took place at One Great George Street, Westminster, on 12th December 2022. The UK as a powerhouse of research.

Life Science 97

Life Science Medicine Clinical Trials Clinical Trials 97

pharmaphorum

JUNE 20, 2022

Paul Verdin, VP of consulting and analytics, and Andreas Hadjivasiliou, managing analyst at Evaluate, tell us about the company’s Orphan Drug Report 2022, which highlights activities within the orphan drug market and forecasts what the future of the industry holds based on data. “The key headline is that rare diseases are not a niche.

Drugs 52

Drugs Marketing Life Science Regulation 52

XTalks

JULY 10, 2023

Xtalks spoke with Kaushik Gune, Head of Healthcare (US) at Huma, a global digital health technology company, to learn more about SaMD and what it looks like to create a regulated health app. What are some examples of software as a medical device (SaMD) and how is this software regulated? Tier one devices represent the low risk.

Life Science 52

Life Science Cardiology Regulation Pharma Companies 52

pharmaphorum

DECEMBER 16, 2020

We’ve got so many great life science assets in the UK, but there are still some gaps – manufacturing capacity being one of them.”. “We We had companies collaborating to develop laboratories. We had companies sourcing consumables for testing machines. A collaborative future.

Vaccination 120

Vaccination Vaccine Life Science In-Vitro 120

pharmaphorum

MAY 27, 2022

Once stakeholders are confident that technologies are adequately validated, selection based on scientific and ethical considerations can be presented to regulators in accordance with applicable legal and regulatory frameworks. There is a huge opportunity for pharma companies to capitalise on by focusing on increased DEI in clinical trials.

Clinical Trials 78

Clinical Trials Clinical Trials Trials Packaging 78

pharmaphorum

MARCH 26, 2021

The UK Government and EU Commission trumpeted their Brexit trade deal, struck at the end of December, as ‘comprehensive’, the ‘biggest yet’ But a closer inspection of the EU-UK Trade and Cooperation Agreement (TCA) renders these statements largely illusory for the pharma sector. About the author.

Production 118

Production Medicine Marketing Regulation 118

pharmaphorum

MAY 14, 2021

Long headquartered in London, the EU drug regulator is now severed from the country both physically and systematically, with its base now in Amsterdam and the UK now assessing drugs through its own regulatory agency, MHRA.

Marketing 57

Marketing Regulation Medicine Life Science 57

pharmaphorum

DECEMBER 16, 2022

There are already rules that dictate how countries should react against public health events that have the potential to traverse country borders, through the International Health Regulations. The industry has so far resisted demands for the sharing of intellectual property (IP) around products developed to counter the pandemic.

Vaccination 96

Vaccination Vaccine Production Licensing 96

pharmaphorum

JUNE 10, 2022

To compete now, companies need to own a larger portion of the treatment journey and the overall patient care experience. Commercial leaders should leverage the internal capabilities and centres of excellence that pharma companies are increasingly building. About BrightInsight.

Marketing 132

Marketing Engineer Bioinformatics Regulation 132

Drug Discovery World

FEBRUARY 6, 2024

However, many have cautioned against too great a reliance on these tools and emphasised the importance of checks and balances to ensure the systems are properly regulated and results are verified. By making lab automation as easy as using a smartphone, the Flex robot democratises access to automation in life sciences research.”

Marketing 69

Marketing Medicine Genome Genomics 69

pharmaphorum

JANUARY 26, 2021

No more ‘business as usual’ for pharma’s customer engagement. Life sciences companies need to rethink their customer engagement paradigms in light of changing customer preferences. Pharma companies will need to continually rethink what works and not be afraid to experiment with solutions they’ve never tried before.

Clinical Trials 141

Clinical Trials Clinical Trials Sales Life Science 141

pharmaphorum

OCTOBER 3, 2022

Gaurav Kapoor, co-founder and executive vice president of Indegene, tells pharmaphorum how pharma can take lessons from the entertainment industry and prepare for the Metaverse to enhance content engagement. Pharma companies’ customer communication methods require reimagining as technology progresses. About the author.

Branding 113

Branding Doctors Doctor Compliance 113

Cloudbyz

MAY 19, 2021

Introduction Cell and gene therapy is an upcoming wave of therapeutic innovation in the healthcare and life sciences industry and is being pragmatically accepted worldwide. However, the major challenge is the newness and uncharted territory of the CGT field for service companies.

Gene Therapy 52

Gene Therapy Gene Manufacturing Production 52

The Pharma Data

DECEMBER 17, 2020

Prior to joining Clarify, Gulati was a partner at McKinsey and Company, working with the Life Science, Medical Products and Health Systems practices in the US and EMEA. Recro – CDMO company Recro announced David Enloe as its new president and CEO. AB2 Bio – Swiss pharma company AB2 Bio Ltd.

Development 52

Development Gene Therapy Engineer Life Science 52

XTalks

MAY 11, 2023

Now it’s regulators, payers, academics, patient communities, physicians and industry all asking, “Where have you incorporated the patient voice? Do you think there’s a difference between how large, or more established, pharma companies are trying to incorporate the patient voice versus smaller biotechs?

Clinical Trials 97

Clinical Trials Clinical Trials Trials Development 97

pharmaphorum

APRIL 19, 2021

UK biotech guru Clive Dix has clinched some major deals with big pharma and biotech in the last 12 months, as CEO of C4X Discovery and as head of the UK vaccines taskforce. It’s been eventful 12-month period for the UK biotech guru Clive Dix, who has just seen his company C4X Discovery clinch a major inflammatory diseases deal with Sanofi.

Vaccination 98

Vaccination Vaccine Life Science Antibody 98

Drug Discovery World

JANUARY 5, 2023

Frits Stulp and Aida Demneri , partners at Deloitte (including Iperion – a Deloitte business), outline how life sciences companies can play their part in driving change. It’s this kind of expanded vision for data use the major pharma companies are working towards today. To prepare for anything less would be unwise.

Life Science 52

Life Science Production Medicine Compliance 52

pharmaphorum

MARCH 9, 2021

Regeneron and Eli Lilly have already got antibody therapies on the market following emergency approvals by regulators including the FDA but pharma companies are beginning to focus on the threat posed by emerging variants.

Antibody 98

Antibody Life Science Scientist Vaccination 98

pharmaphorum

NOVEMBER 6, 2020

“We have some partners providing very similar tools to each other, and that’s okay, because we want to provide clients with options… I think that helps foster collaboration and encourages a little bit of healthy competition – which is always good for science”. This fragmented landscape creates issues for pharma. “If,

Life Science 58

Life Science Pharma Companies Production Development 58

XTalks

MARCH 22, 2023

In October 2022, Xtalks celebrated two decades of bringing diverse stakeholders in the life science industry together through first holding physical events, then soon after, hosting exclusively online events. In that time, we’ve gone from running 25 webinars each year to over 400, working with more than 800 expert speakers each year.

Life Science 97

Life Science Drugs FDA Approval Vaccination 97

XTalks

JANUARY 11, 2021

Companies outsource to gain access to specialized expertise and technology, scale pharmacovigilance (PV) activities, and reduce costs. However, the efficiency and effectiveness of externalized safety activities are below expectations for many biotech and pharma companies.

Pharma Companies 90

Pharma Companies Compliance Clinical Outsourcing Regulation 90

Delveinsight

SEPTEMBER 8, 2021

Especially in the field of Pharmaceutical & Life Sciences, a company’s all-around product life-cycle stages, which consist of planning, designing, constructing, product testing, and commissioning processes are provided by a Pharma Consultant. Pharma Consultant. Market Assessment & Operational Sales.

Marketing 52

Marketing Production Sales Life Science 52